Walter Stadler, MD, is an expert in prostate, kidney, bladder, and testicular cancers. He concentrates on the use of chemotherapy, immunotherapy, anti-angiogenic therapy, and molecularly targeted therapy for patients with locally advanced or metastatic disease.
His research focuses on the development of new treatments for these urological cancers. Dr. Stadler's research includes development of molecular and imaging markers for predicting response to various anti-cancer therapies.
Dr. Stadler has authored and co-authored more than 200 articles in medical journals such as Cancer Research and the Journal of Clinical Oncology, in addition to more than 100 book chapters, reviews, letters, and editorials. He is an active member of several committees and boards, including the medical advisory boards of the Kidney Cancer Association and the Bladder Cancer Advocacy Network, and the editorial board of UpToDate in Oncology, an information source for oncologists.
Specialties
Areas of Expertise
- Bladder Cancer
- Testicular Cancer
- Prostate Cancer
- Renal Cancer
- Kidney Cancer
Board Certifications
- Internal Medicine
- Medical Oncology
Memberships & Medical Societies
- American Federation for Medical Research
- American Society of Clinical Oncology
- American College of Physicians
- American Association for Cancer Research
- American Association for the Advancement of Science
- American Urological Association
- Society of Urologic Oncology
Practicing Since
- 1994
Languages Spoken
- English
- German
Medical Education
- Yale University School of Medicine
Internship
- Michael Reese Hospital
Residency
- Michael Reese Hospital
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
- CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
- Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
- Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
To Request an Appointment
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient